Press Releases
Keyword Search
| Date | Title | ||
|---|---|---|---|
|
09/30/20
|
Summary ToggleT2 Biosystems Announces BARDA Exercise of Contract Option 1 Valued at $10.5 Million |
|
Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens LEXINGTON, Mass. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that the Biomedical |
|
09/16/20
|
Summary ToggleT2 Biosystems to Participate in Sepsis Alliance Summit |
|
Summit will raise awareness and highlight the critical role of rapid diagnostics for bloodstream infections, sepsis and the COVID-19 virus LEXINGTON, Mass. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today |
|
09/04/20
|
Summary ToggleT2 Biosystems Announces CMS Approval of a New Technology Add-On Payment for the T2Bacteria® Panel for a Second Year |
|
Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients LEXINGTON, Mass. , Sept. 04, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the U.S. |
|
08/31/20
|
Summary ToggleT2 Biosystems Receives FDA Emergency Use Authorization for COVID-19 Molecular Diagnostic Test |
|
The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument LEXINGTON, Mass. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the U.S. Food and Drug Administration (FDA) has issued |
|
08/11/20
|
Summary ToggleT2 Biosystems Announces Second Quarter 2020 Financial Results |
|
LEXINGTON, Mass. , Aug. 11, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the second quarter ended June 30, 2020 . Recent Highlights Achieved second quarter total revenue of $2.6 |
|
08/05/20
|
Summary ToggleT2 Biosystems Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock Split |
|
LEXINGTON, Mass. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that its Board of Directors has decided it will not seek authority from the stockholders at the 2020 Annual Meeting (“Annual Meeting”) |
|
07/30/20
|
Summary ToggleT2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference |
|
LEXINGTON, Mass. , July 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming virtual Canaccord Genuity Annual Growth Conference. |
|
07/28/20
|
Summary ToggleT2 Biosystems to Report Second Quarter 2020 Financial Results on August 11, 2020 |
|
LEXINGTON, Mass. , July 28, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the second quarter of 2020 after market close on Tuesday, August 11, 2020. |
|
06/30/20
|
Summary ToggleT2 Biosystems Announces U.S. Launch of COVID-19 Diagnostic Test |
|
The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument LEXINGTON, Mass. , June 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the completion of validation of its COVID-19 molecular |
|
06/30/20
|
Summary ToggleT2 Biosystems Announces Preliminary Second Quarter 2020 Financial Results |
|
Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines LEXINGTON, Mass. , June 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced unaudited preliminary financial result estimates for the quarter ended June |